Citadel Advisors
ESLA icon

Citadel Advisors’s Estrella Immunopharma ESLA Stock Holding History

Citadel Advisors’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-64,394
Closed -$100K – 13293
2025
Q4 		$100K Buy
64,394
+14,272
+28% +$27K ﹤0.01% 11637
2025
Q3 		$59.6K Sell
50,122
-34
-0.1% -$33 ﹤0.01% 12104
2025
Q2 		$43K Sell
50,156
-41,443
-45% -$40.2K ﹤0.01% 11841
2025
Q1 		$84.9K Buy
+91,599
New +$101K ﹤0.01% 11695
2024
Q4 		– Sell
-14,531
Closed -$16.9K – 14728
2024
Q3 		$16.9K Buy
+14,531
New +$18.7K ﹤0.01% 12910

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Citadel Advisors's ESLA Position: Q1 2026 in Review

Citadel Advisors sold out of Estrella Immunopharma (ESLA) in Q1 2026, closing a stake of 64,394 shares — an estimated $100K sold.

Citadel Advisors first reported a position in ESLA in Q3 2024 and held it in 5 quarters. The position peaked at $100K in Q4 2025. 16 funds tracked by Wall St. Rank hold ESLA as of Q1 2026.

  • Citadel Advisors reported no remaining Estrella Immunopharma position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 64,394 Estrella Immunopharma shares in Q1 2026, an estimated $100K.
  • Citadel Advisors first reported a position in Estrella Immunopharma in Q3 2024 and held it in 5 quarters.
  • Citadel Advisors's Estrella Immunopharma position peaked at $100K in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.